Ramirez et al used, males were exclusively used significantly more often when mice, rats, rabbits, or a combination of animal models was used (accounting for 95.0% of studies).
The number of preclinical studies published yearly over the past decade has remained stable; however, there has been a significant increase in the proportion using exclusively males and a significant decrease in the proportion using exclusively females. There have not been significant changes in the proportions of studies using both sexes or reporting the sex of the animals used (Figure) . These trends were unchanged when studies in which sex was not specified were excluded.
Sex-based reporting of results occurred in 35.1% of studies in which sex was reported using the liberal criterion of any results being reported in reference to the sex of the animals used at least once. There was no appreciable difference in the prevalence of sex-based reporting before and after the publication of planned National Institutes of Health policies to improve sex inclusion in preclinical research 1 (34.9% versus 35.7%, respectively). Of the 2297 studies in which only 1 sex was reportedly used, 1.6% mentioned this aspect of the study design as a potential limitation.
Although the need to include women in clinical trials is now a well-established requirement to enhance external validity, analogous standards have not gained a foothold in preclinical stages. Reasons put forward for the preferential use of males include increased variability attributable to fluctuating gonadal hormone levels throughout the estrous cycle and sample size implications of planning sexbased analyses. 2, 3 Evidence to support these concerns is limited for most experimental settings, however. [3] [4] [5] Our review of preclinical research published in leading cardiovascular journals over the past 10 years demonstrates that sex bias is prevalent and increasing, contrasting with advances made in clinical research designs and reporting. Concerted efforts on the part of researchers, journal editors, peer reviewers, universities, industry, professional organizations, and patient advocacy groups are urgently needed to address this discrepancy. A, Absolute number of preclinical studies published and sex of animals used as a function of time. r denotes Pearson correlation coefficient for the total number of studies over time. B, Sex of animals used in preclinical studies over time (%). P trend calculated for the proportion of studies using exclusively males, exclusively females, both sexes, and not reporting the sex of the animals used over time.
